<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35405282</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3476</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>620</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of pharmaceutics</Title>
          <ISOAbbreviation>Int J Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization.</ArticleTitle>
        <Pagination>
          <StartPage>121725</StartPage>
          <MedlinePgn>121725</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2022.121725</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0378-5173(22)00280-0</ELocationID>
        <Abstract>
          <AbstractText>Choroidal neovascularization (CNV) is a prevalent vision-threatening vascular disorder in aging population. CNV is associated with several diseases in the posterior segment of the eye such as age-related macular degeneration (AMD). In this study we developed sunitinib-loaded liposomes to block the neovascularization signalling pathway through inhibition of tyrosine kinase of vascular endothelial growth factor receptors (VEGFRs). Liposomal sunitinib formulations were prepared by thin film hydration method and studied for their encapsulation efficiency (EE), loading capacity (LC) and drug release profile in buffer andvitreous. Our finding showed that the liposomes (mean size 104 nm) could effectively entrap sunitinib (EE ≈ 95%) at relatively high loading capacity (LC ≈ 5%) and release sunitinib over at least 3 days. Intravitreal sunitinib-loaded liposomes revealed inhibitory effect on established neovascularization in laser-induced CNV mouse model while the intravitreal injection of sunitinib solubilized with cyclodextrin was inefficient in management of neovascularization. Accordingly, liposomal sunitinib is a promising drug delivery system that should be further studied to inhibit the CNV related to AMD.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Tavakoli</LastName>
            <ForeName>Shirin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 University of Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Puranen</LastName>
            <ForeName>Jooseppi</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bahrpeyma</LastName>
            <ForeName>Sina</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lautala</LastName>
            <ForeName>Veera E</ForeName>
            <Initials>VE</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 University of Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Karumo</LastName>
            <ForeName>Suvi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 University of Helsinki, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lajunen</LastName>
            <ForeName>Tatu</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 University of Helsinki, Finland; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland; Laboratory of Pharmaceutical Technology, Department of Pharmaceutical Science, Tokyo University of Pharmacy &amp; Life Sciences, 1432-1 Hachioji 192-0392, Tokyo, Japan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del Amo</LastName>
            <ForeName>Eva M</ForeName>
            <Initials>EM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ruponen</LastName>
            <ForeName>Marika</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Urtti</LastName>
            <ForeName>Arto</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, FI-00790 University of Helsinki, Finland; School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, Yliopistonranta 1, 70210 Kuopio, Finland. Electronic address: arto.urtti@helsinki.fi.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Pharm</MedlineTA>
        <NlmUniqueID>7804127</NlmUniqueID>
        <ISSNLinking>0378-5173</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>V99T50803M</RegistryNumber>
          <NameOfSubstance UI="D000077210">Sunitinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020256" MajorTopicYN="Y">Choroidal Neovascularization</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058449" MajorTopicYN="N">Intravitreal Injections</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008268" MajorTopicYN="Y">Macular Degeneration</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077210" MajorTopicYN="N">Sunitinib</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Age-related macular degeneration</Keyword>
        <Keyword MajorTopicYN="N">Choroidal neovascularization</Keyword>
        <Keyword MajorTopicYN="N">Cyclodextrin</Keyword>
        <Keyword MajorTopicYN="N">Intravitreal injection</Keyword>
        <Keyword MajorTopicYN="N">Liposome</Keyword>
        <Keyword MajorTopicYN="N">Sunitinib</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>11</Day>
          <Hour>20</Hour>
          <Minute>11</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35405282</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijpharm.2022.121725</ArticleId>
        <ArticleId IdType="pii">S0378-5173(22)00280-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
